Xenon Pharmaceuticals Inc.

XENE | NASDAQ

Price Alert Chart Builder DCF Calculator

$38.10

-$0.89 (-2.28%)

Sep 22, 2026, 12:28 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $3.77B

Enterprise Value $2.84B

Beta 0.62

Average Volume 1.18M

Shares Outstanding (Diluted) 99.61M

Shares Change YoY 26.16%

Institutional Ownership N/A

Exchange NASDAQ

ISIN CA98420N1050

Price Performance

Price Change 1M -36.0%

Price Change 3M -28.6%

Price Change 6M -29.8%

Price Change YTD -12.4%

Price Change 1Y 4.4%

Price Change 3Y 10.9%

Price Change 5Y 158.7%

1M CAGR (ann.) -38.5%

1Y CAGR (ann.) 3.3%

5Y CAGR (ann.) 17.1%

All-Time CAGR 11.7%

Valuation

PE Ratio -8.23

Forward PE N/A

PEG Ratio 0.30

Forward PEG -5.18

PS Ratio N/A

Forward PS 139.70

PB Ratio 3.03

P/FCF Ratio -8.82

P/Adj. FCF Ratio -7.45

P/OCF Ratio -11.50

EV/Sales N/A

EV/EBIT -6.80

EV/EBITDA -6.83

EV/FCF -6.65

Earnings Yield -12.2%

FCF Yield -11.3%

Adj. FCF Yield -13.4%

Financial Health

Net Cash $924.27M

Total Debt $6.42M

Cash & Short-Term Investments $930.69M

Total Assets $1.3B

Current Ratio 21.02

Quick Ratio 21.02

Debt / Equity Ratio 0.01

Debt / EBITDA -0.02

Debt / FCF -0.02

OCF / Debt -66.44

Interest Coverage 0.00

Altman Z-Score 40.56

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -18.3%

Returns

Return on Assets -31.6%

Return on Equity -44.0%

Return on Invested Capital -35.1%

Return on Capital Employed -35.3%

Return on Tangible Assets -31.6%

Historical Growth (CAGR)

Revenue CAGR 3Y 0.0%

Revenue CAGR 5Y -60.7%

Revenue CAGR 10Y -4.9%

EPS CAGR 3Y -27.2%

EPS CAGR 5Y -21.9%

EPS CAGR 10Y -13.7%

FCF CAGR 3Y -49.1%

FCF CAGR 5Y -39.1%

FCF CAGR 10Y -30.7%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 22

EPS Growth Next 3Y 37.0%

Revenue Growth Next 3Y N/A

Earnings Date Nov 1, 2026

EPS Estimate (next Q) -$1.17

EPS Growth Est (next Q) 1.7%

Revenue Est (next Q) $1.33M

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $65.57

Price Target Upside 68.2%

Cash Flow

Operating Cash Flow $-426.42M

Free Cash Flow $-427.56M

Adj. Free Cash Flow $-505.9M

FCF Per Share -$3.40

OCF Per Share -$3.39

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-77.67M

Operating Income $-441.59M

EBITDA $-416.75M

Net Income $-409.2M

EPS (Diluted) -$4.74

Revenue / Employee N/A

Profit / Employee $-1.12M

Employees 364